IPCA Laboratories Limited reported standalone revenue from operations of Rs 7,336.75 crore for the financial year ended March 31, 2026, compared to Rs 6,677.92 crore in the previous year. Net profit for the year stood at Rs 1,132.52 crore, against Rs 650.76 crore in FY2025.
For the fourth quarter ended March 31, 2026, standalone revenue from operations was Rs 1,814.35 crore, up from Rs 1,638.44 crore in the corresponding quarter last year. Net profit for the quarter was Rs 262.29 crore, compared to a net loss of Rs 65.05 crore in the same period a year ago.
Earnings per share for FY2026 after exceptional items stood at Rs 44.64, compared to Rs 25.65 in FY2025. Before exceptional items, EPS for the full year was Rs 45.84, against Rs 36.75 in the prior year. For the March quarter, EPS after exceptional items was Rs 10.34, compared to a loss per share of Rs 2.56 in the year-ago quarter.
The board recommended a final dividend of Rs 6 per equity share of face value Rs 1 each, representing 600 percent for the financial year ended March 31, 2026. The dividend is subject to shareholder approval. IPCA Laboratories fixed August 7, 2026 as the record date for determining member entitlement to the dividend, if approved.
The standalone results include an exceptional item of Rs 30.42 crore for the year, reflecting the impact of new labour codes notified by the Government of India. The board approved the audited standalone and consolidated financial results at its meeting held on May 29, 2026.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.